These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31314954)

  • 1. The effect of intradermal microdosing of a transient receptor potential cation channel subfamily V member 1 antagonist on heat evoked pain and thermal thresholds in normal and ultraviolet-C exposed skin in healthy volunteers.
    Sjögren E; Ståhle L; Quiding H; Jonzon B; Halldin MM; Sundgren AK
    Eur J Pain; 2019 Nov; 23(10):1767-1779. PubMed ID: 31314954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical testing of three novel transient receptor potential cation channel subfamily V member 1 antagonists in a pharmacodynamic intradermal capsaicin model.
    Sjögren E; Kullenberg T; Jonzon B; Segerdahl M; Stålberg O; Halldin MM; Sundgren-Andersson AK
    Eur J Pain; 2018 Aug; 22(7):1214-1228. PubMed ID: 29504187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile.
    Arendt-Nielsen L; Harris S; Whiteside GT; Hummel M; Knappenberger T; O'Keefe S; Kapil R; Kyle D
    Pain; 2016 Sep; 157(9):2057-2067. PubMed ID: 27168361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial.
    Rowbotham MC; Nothaft W; Duan RW; Wang Y; Faltynek C; McGaraughty S; Chu KL; Svensson P
    Pain; 2011 May; 152(5):1192-1200. PubMed ID: 21377273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
    Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
    Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist.
    Brown W; Leff RL; Griffin A; Hossack S; Aubray R; Walker P; Chiche DA
    J Pain; 2017 Jun; 18(6):726-738. PubMed ID: 28188907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
    Wouters MM; Balemans D; Van Wanrooy S; Dooley J; Cibert-Goton V; Alpizar YA; Valdez-Morales EE; Nasser Y; Van Veldhoven PP; Vanbrabant W; Van der Merwe S; Mols R; Ghesquière B; Cirillo C; Kortekaas I; Carmeliet P; Peetermans WE; Vermeire S; Rutgeerts P; Augustijns P; Hellings PW; Belmans A; Vanner S; Bulmer DC; Talavera K; Vanden Berghe P; Liston A; Boeckxstaens GE
    Gastroenterology; 2016 Apr; 150(4):875-87.e9. PubMed ID: 26752109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers.
    Lee J; Kim BH; Yu KS; Kim HS; Kim JD; Cho JY; Lee S; Gu N
    Drug Des Devel Ther; 2017; 11():1301-1313. PubMed ID: 28479852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
    Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
    Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects.
    Zhang Y; Wang K; Arendt-Nielsen L; Cairns BE
    Eur J Pain; 2018 Feb; 22(2):393-401. PubMed ID: 29024230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cav3.2-expressing low-threshold C fibres in human hairy skin contribute to cold allodynia--a non-TRPV1- and non-TRPM8-dependent phenomenon.
    Samour MS; Nagi SS; Mahns DA
    Pain; 2015 Aug; 156(8):1566-1575. PubMed ID: 25932689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of three transient receptor potential vanilloid receptor 1 antagonists for early use in human intradermal microdose analgesic studies.
    Sjögren E; Halldin MM; Stålberg O; Sundgren-Andersson AK
    Eur J Pain; 2018 May; 22(5):889-903. PubMed ID: 29377430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intradermal administration of magnesium sulphate and magnesium chloride produces hypesthesia to mechanical but hyperalgesia to heat stimuli in humans.
    Ushida T; Iwatsu O; Shimo K; Tetsunaga T; Ikeuchi M; Ikemoto T; Arai YC; Suetomi K; Nishihara M
    J Neuroinflammation; 2009 Aug; 6():25. PubMed ID: 19715604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.
    Schaffler K; Reeh P; Duan WR; Best AE; Othman AA; Faltynek CR; Locke C; Nothaft W
    Br J Clin Pharmacol; 2013 Feb; 75(2):404-14. PubMed ID: 22775239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain.
    Krarup AL; Ny L; Astrand M; Bajor A; Hvid-Jensen F; Hansen MB; Simrén M; Funch-Jensen P; Drewes AM
    Aliment Pharmacol Ther; 2011 May; 33(10):1113-22. PubMed ID: 21410733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The time course of brief and prolonged topical 8% capsaicin-induced desensitization in healthy volunteers evaluated by quantitative sensory testing and vasomotor imaging.
    Lo Vecchio S; Andersen HH; Arendt-Nielsen L
    Exp Brain Res; 2018 Aug; 236(8):2231-2244. PubMed ID: 29845449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath.
    Tékus V; Bölcskei K; Kis-Varga A; Dézsi L; Szentirmay E; Visegrády A; Horváth C; Szolcsányi J; Petho G
    Eur J Pharmacol; 2010 Sep; 641(2-3):135-41. PubMed ID: 20534382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
    Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
    J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effect of Incobotulinumtoxin A on pain, neurogenic flare and hyperalgesia in human surrogate models of neurogenic pain.
    Diener SA; Breimhorst M; Vogt T; Krämer HH; Drummond PD; Geber C; Birklein F
    Eur J Pain; 2017 Sep; 21(8):1326-1335. PubMed ID: 28440002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
    Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
    J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.